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Aim: Most statins increase the risk of new-onset diabetes. Unlike other statins, pitavastatin is reported to exert 
neutral effects on serum glucose level, but the precise mechanism is unknown.
Methods: Eight-week-old male C57BL/6J mice (n=26) were fed high-fat diet (HFD, 45% fat) with 0.01% pla-
cebo, rosuvastatin, or pitavastatin for 12 weeks. Cultured HepG2, C2C12, and 3T3-L1 cells and visceral adipo-
cytes from HFD-fed mice were treated with vehicle or 10 µM statins for 24 h. The effects of pitavastatin and 
rosuvastatin on intracellular insulin signaling and glucose transporter 4 (GLUT4) translocation were evaluated. 
Results: After 12 weeks, the fasting blood glucose level was significantly lower in pitavastatin-treated group 
than in rosuvastatin-treated group (115.2±7.0 versus 137.4±22.3 mg/dL, p=0.024). Insulin tolerance signifi-
cantly improved in pitavastatin-treated group as compared with rosuvastatin-treated group, and no significant 
difference was observed in glucose tolerance. Although plasma adiponectin and insulin levels were not different 
between the two statin treatment groups, the insulin-induced protein kinase B phosphorylation was weakly 
attenuated in pitavastatin-treated adipocytes than in rosuvastatin-treated adipocytes. Furthermore, minor attenu-
ation in insulin-induced GLUT4 translocation to the plasma membrane of adipocytes was observed in pitavas-
tatin-treated group.
Conclusion: Pitavastatin showed lower diabetogenic effects than rosuvastatin in mice that may be mediated by 
minor attenuations in insulin signaling in adipocytes. 
cise mechanism is incompletely known. Several possi-
ble mechanisms have been hypothesized, including 
the effect of statins on the survival of pancreatic beta 
cells, reduction in insulin secretion, enhancement in 
hepatic glucose production, increased insulin resis-
tance through the disruption of intracellular insulin 
signaling, and disturbance of glucose uptake in the 
peripheral tissues such as muscle and fat8-12). Whether 
these effects are common to all statins is questionable. 
Background
Statins are 3-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA) reductase inhibitors that are proven to 
be beneficial and widely used for the prevention of 
cardiovascular diseases1-4). However, several clinical tri-
als have shown that statins may increase the risk of 
new-onset diabetes mellitus (NOD)5-7). Although 
statins cause significant diabetogenic effects, the pre-
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Aldrich, St. Louis, MO, USA) was intraperitoneally 
injected (0.75 U/kg body weight) and blood samples 
from the tail vein were collected at 15, 30, 60, 90, and 
120 min after insulin injection. Glucose levels were 
evaluated with Accu-Chek Performa glucometer 
(Boehringer-Mannheim, Indianapolis, IN, USA). 
Fasting Plasma Insulin and Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR) 
The blood samples collected after 8 h of fasting 
were used for the quantification of plasma insulin level 
with an enzyme-linked immunosorbent assay (ELISA), 
according to the manufacturer’s recommendations 
(EZRMI-13K, EMD Millipore Corporation, St. 
Charles, MO, USA). HOMA-IR was estimated from 
fasting glucose and insulin as follows:
HOMA-IR= fasting insulin (µU/mL)×fasting 
glucose (mg/dL)/405 18).
Measurement of Plasma Total Adiponectin and 
High Molecular Weight (HMW) Adiponectin Levels 
The blood samples were collected in microcentri-
fuge tubes and centrifuged to obtain the serum. Serum 
adiponectin and HMW adiponectin levels were mea-
sured using mouse ELISA kits (47-ADPMS-D01, 
ALPCO, Salem, NH, USA). 
Cell Culture and Drug Treatment
The hepatocellular carcinoma cell line, HepG2, 
was cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (SV30010) in a 5% CO2 incubator at 37℃. 
The immortalized murine myoblast cell line, C2C12, 
was cultivated in Eagle’s Minimum Essential Medium 
supplemented with 2 mM L-glutamine, 10% dialyzed 
FBS, and antibiotics19). Preadipocyte 3T3-L1 cells 
were cultured in a differentiation medium20). Rosuvas-
tatin (SML1264, Sigma-Aldrich, St. Louis, MO, 
USA) and pitavastatin (CAS 147526-32-7, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) were dissolved 
in dimethyl sulfoxide before dilution in the culture 
medium. In all experiments, the final statin and 
dimethyl sulfoxide concentrations were 10 µM and 
0.1%, respectively. 
Western Blot Analysis for Protein Kinase B (Akt) 
and Phosphorylated Akt
Primary adipocytes from the mouse visceral adi-
pose tissue and 3T3-L1, HepG2, and C2C12 cells 
were pretreated with 10 µM pitavastatin or rosuvas-
tatin for 24 h, serum-starved for 4 h with or without 
statins, and stimulated with 100 nM insulin for 5 to 
15 min. Cell lysates were obtained from each treat-
In comparison with other statins, pitavastatin exhib-
ited neutral effects on serum glucose and NOD risk7, 13). 
In addition, pitavastatin does not appear to increase 
glucose or glycated hemoglobin level13-15). A recent 
meta-analysis revealed the absence of any association 
between pitavastatin and increased risk of NOD16). 
There are several hypothetical mechanisms 
explaining the action of pitavastatin on glucose metab-
olism. The pharmacological profile and effects of 
pitavastatin on adiponectin were thought to be related 
to its influence on glucose metabolism17). How 
pitavastatin affects glucose metabolism is, however, 
still unclear. Here, we investigated the effects of 
pitavastatin on glucose metabolism by focusing on 
insulin sensitivity, glucose tolerance, intracellular insu-
lin signaling, and adiponectin levels in diet-induced 
obese mice and under in vitro conditions. 
Materials and Methods
Animals
Six-week-old male C57BL/6J mice were housed 
under standard conditions (21±2℃, 60±10% 
humidity, 12 h light/dark cycle) with ad libitum access 
to food and water. The mice were fed a high-fat diet 
(HFD, including 45% fat, n=6), HFD with rosuvas-
tatin (0.01%, n=10), or HFD with pitavastatin 
(0.01%, n=10) for 12 weeks beginning from 8 weeks 
of age. Food intake, fasting blood glucose, and body 
weight were measured twice a week (in the evening 
after 8 h of fasting). After 12 weeks, the mice were 
euthanized under anesthesia and the blood samples 
were collected by cardiac puncture. The liver and epi-
didymal fat tissues were isolated from each mouse and 
weighed. All animal procedures were performed in 
accordance with the guidelines from the National 
Institutes of Health and pre-approved by the animal 
care and use committee at the Yonsei University, Col-
lege of Medicine (2014-0304). 
Oral Glucose Tolerance Test (OGTT) and Insulin 
Tolerance Test (ITT)
OGTT and ITT were performed after the mice 
had received the test diet for 11 weeks at 19 weeks of 
age. After 8 h of fasting, the baseline blood glucose 
level was measured by tail vein puncture. For OGTT, 
a solution of 40% glucose (2 g/kg body weight) was 
administered by oral gavage. After glucose administra-
tion, blood samples were collected from the tail vein 
at 15, 30, 60, 90, and 120 min. Blood glucose levels 
were measured using Accu-Chek Performa glucometer 
(Boehringer-Mannheim, Indianapolis, IN, USA). 
For ITT, the mice were fasted for 8 h under non-
anesthetized conditions. Insulin-R (I9278, Sigma-
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Statistical Analysis 
All data are presented as the mean±standard 
deviation (SD). Statistical analyses were performed 
with t-test, analysis of variance (ANOVA), or repeated 
measures ANOVA with Dunnett’s t-test for multiple 
comparisons as appropriate. A value of p＜0.05 was 
considered significant. Analysis was performed using 
SPSS Statistics version 23.0 (IBM Co., Somers, NY, 
USA).
Results
Biochemical Characteristics of Mice 
The characteristics of mice from different groups 
are described in Table 1. Baseline body weight was the 
lowest among the mice from rosuvastatin group. At 
the end of the treatment (after 12 weeks), no differ-
ence was observed in the body weight and degree of 
weight gain between all groups. Furthermore, the 
mean liver weight and fat mass were not significantly 
different among the mice from the three groups (all p
＞0.05). 
No difference in body weight gain was observed 
between pitavastatin and rosuvastatin treatment 
groups over the 12-week study period (Fig.1a). No 
statistical difference was reported in food intake 
among the three groups (Fig.1b). However, fasting 
blood glucose level was significantly lower in pitavas-
tatin group than in rosuvastatin group after 12 weeks 
of treatment (115.2±7.0 mg/dL in pitavastatin group 
versus 137.4±22.3 mg/dL in rosuvastatin group, p=  
0.024, Fig.1c).
Effects of Pitavastatin and Rosuvastatin on Glucose 
and Insulin Tolerance
The results of OGTT showed that the mice from 
pitavastatin group exhibited a significant improve-
ment in glucose tolerance as compared with those 
from control and rosuvastatin groups at 0, 30, and 
ment group. 
Equal amounts of proteins were electrophoresed 
on sodium dodecyl sulfate polyacrylamide gels and the 
separated protein bands were transferred onto polyvi-
nylidene fluoride membranes. After blocking, the 
membranes were incubated with phospho-Akt serine 
473 (#9271, Cell Signaling Technology, Denver, MA, 
USA), phospho-Akt threonine 308 (#9275), and pan-
Akt (#9272) antibodies, followed by treatment with 
horseradish peroxidase-conjugated anti-rabbit IgG (sc-
2030, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). The blots were developed using an enhanced 
chemiluminescence detection kit. Equal loading was 
verified by re-probing the blot with β-actin (A5441, 
Sigma, St Louis, MO, USA) antibody.
2-Deoxyglucose (2-DG) Uptake and Glucose 
Transporter 4 (GLUT4) Translocation Staining
2-DG uptake into 3T3-L1 cells was measured 
using Glucose Uptake Colorimetric Assay Kit 
(ab136955, Abcam Inc. Cambridge, MA, USA) 
according to the manufacturer’s protocol. Measure-
ments were performed in triplicates and the average 
value was recorded. 
GLUT4 staining was conducted as previously 
described21). After stimulation with 100 nM insulin 
for 30 min, the cells were fixed on coverslips with 4% 
paraformaldehyde and permeabilized with 0.25% Tri-
ton X-100. GLUT4 level was detected by incubation 
with a polyclonal primary antibody (ab654, Abcam 
Inc. Cambridge, MA, USA) using standard proce-
dures. After washing with phosphate-buffered saline 
(PBS), the binding of the primary antibody was 
detected with an Alexa-Fluor 488-conjugated second-
ary antibody (A21206, Invitrogen, Carlsbad, CA, 
USA). Coverslips were mounted with ProLong Gold 
antifade medium (P36934, Invitrogen, Carlsbad, CA, 
USA) and imaged using LSM700 laser confocal 
microscope (Zeiss, Jena, Germany). 















































and 20,139.6±2,070.8 ng/dL in pitavastatin, HFD, 
and rosuvastatin groups, respectively; p=0.105) 
(Fig.4a). No significant differences were observed in 
HMW adiponectin levels between the three groups 
(p=0.653, Fig.4b). 
Effects of Pitavastatin and Rosuvastatin on Insulin 
Signaling 
To analyze the effect of pitavastatin on insulin 
response in the liver, we evaluated the phosphoryla-
tion level of Akt after 15 min from stimulation of 
HepG2 cells with insulin. No significant difference 
was observed in the level of Akt phosphorylation at 
serine 473 and threonine 308 in HepG2 cells from 
the three groups (all p＞0.05 versus control＋insulin 
group, Fig.5a). 
Intracellular insulin signaling level in the muscle 
was analyzed using C2C12 cells (Fig.5b). After 15 
min of insulin administration, no significant differ-
ence was observed in Akt phosphorylation level at ser-
ine 473 and threonine 308 among the three insulin-
stimulated groups (all p＞0.05 versus control＋insulin 
group).
To confirm the role of statins in the adipose tis-
sue, intracellular insulin signaling was investigated in 
3T3-L1 adipocytes (after differentiation). After insulin 
stimulation, Akt phosphorylation level at serine 473 
and threonine 308 showed attenuated pattern in rosu-
vastatin-treated cells as compared with control cells 
(Fig.5c). Akt phosphorylation at serine 473 showed a 
decreasing trend in rosuvastatin group as compared 
120 min after glucose administration (all p＜0.05, 
Fig.2a). The area under the curve (AUC) value of 
OGTT was lower for pitavastatin group than for 
HFD and rosuvastatin groups, but no statistically sig-
nificant difference was reported (Fig.2b, p=0.080).
Insulin tolerance improved in pitavastatin group 
as compared with the control group at 15 and 60 min 
after insulin administration (all p＜0.05, Fig.2c). Fur-
thermore, the AUC value of ITT significantly reduced 
in both pitavastatin and rosuvastatin groups (Fig.2d, 
p=0.008 for pitavastatin and p=0.013 for rosuvas-
tatin). 
Effects of Pitavastatin and Rosuvastatin on Plasma 
Insulin and Insulin Resistance
The mean plasma insulin concentration was 
11.2, 9.2, and 8.8 µU/mL in the control, rosuvastatin, 
and pitavastatin groups, respectively (Fig.3a). No sig-
nificant difference was reported between the three 
groups, although the plasma insulin level tended to be 
lower in pitavastatin group than in other groups 
(p=0.138). Insulin resistance, as indicated by HOMA-
IR value, was the lowest in pitavastatin group 
(p=0.048, Fig.3b). 
Effects of Pitavastatin and Rosuvastatin on Plasma 
Adiponectin and HMW Adiponectin Levels
The plasma adiponectin level increased in 
pitavastatin group as compared to the control and 
rosuvastatin groups, although no significant difference 
was reported (21,779.9±3,317.5, 17,409.2±3,453.3, 
Fig.1. Changes in body weight, food intake, and fasting glucose
(a) Body weight over 12 weeks, (b) food intake over 12 weeks, and 
(c) fasting glucose level at 12 weeks. Error bars represent standard 
error of mean. ＊p＜0.05. Values of p were generated by one-way 
ANOVA, Dunnett’s post-test. HFD, high-fat diet; Pitava, pitavas-
tatin; Rosuva, rosuvastatin. 
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leads to a decrease in glucose uptake. In 3T3-L1 cells, 
the reduction in 2-DG uptake was observed in rosuv-
astatin group (versus control＋insulin, p=0.042, 
Fig.6a). 
GLUT4 staining showed a significant increase in 
the translocation of GLUT4 to the membrane after 
insulin administration in pitavastatin group than in 
rosuvastatin group (Fig.6b). These observations con-
firm that the difference in glucose uptake between 
adipocytes may arise from the variations in GLUT4 
translocation to the plasma membrane. 
Discussion
In the present study, we evaluated the effects of 
pitavastatin on glucose metabolism in HFD-fed obese 
mice and several cell lines and compared them with 
the effects of a widely used drug, rosuvastatin. In com-
parison with rosuvastatin treatment group, pitavas-
with control group (p=0.054). Furthermore, Akt 
phosphorylation at threonine 308 significantly 
reduced in the presence of rosuvastatin as compared 
with the control group (p=0.002). Akt phosphoryla-
tion in pitavastatin group was not significantly differ-
ent from that observed in the control group (all p＞
0.05). 
The above experiments were also conducted in 
an ex vivo model with primary mouse adipocytes 
obtained from the visceral fat tissue of HFD-fed mice 
(Supplementary Fig.1). The level of Akt phosphory-
lation at threonine 308 was significantly attenuated in 
rosuvastatin group as compared with control group 
after 15 min of insulin administration (p=0.049). 
Attenuation of Akt Phosphorylation Inhibits 
Glucose Uptake and GLUT4 Translocation 
We conducted an experiment to confirm whether 
the attenuation of Akt phosphorylation by statins 
Fig.2. Systemic glucose metabolism evaluated with oral glucose tolerance test and insulin tolerance test
(a) Oral glucose tolerance test, (b) area under the curve of glucose tolerance test, (c) insulin tolerance test, (d) area under the curve of insulin 
tolerance test. Error bars represent standard error of mean.
＊p＜0.05, ＊＊p＜0.01 versus corresponding HFD value. ＃p＜0.05, pitavastatin versus rosuvastatin. 
p values were generated by ANOVA, Dunnett’s post-test.
HFD, high-fat diet; OGTT, oral glucose tolerance test; AUC, area under the curve; Pitava; pitavastatin; Rosuva, rosuvastatin. 
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Fig.3. Plasma insulin levels and HOMA-IR in different treat-
ment groups
(a) Insulin level, (b) HOMA-IR. Error bars represent standard error 
of mean. ＊p＜0.05 versus corresponding HFD value. All p values 
were generated by ANOVA. HFD, high-fat diet; Pitava, pitavas-
tatin; Rosuva, rosuvastatin; HOMA-IR, homeostatic model assess-
ment of insulin resistance. 
Fig.5. Statins differentially 
alter the insulin-
induced phosphory-
lation of Akt in cul-
tured cells
Cells were treated with 10 µM 
of statins for 24 h, followed 
by insulin stimulation for 5 to 
15 min. (a) HepG2 cells, (b) 
C2C12 cells, (c) 3T3-L1 cells. 
Representative western blots 
are shown above the plots of 
densitometric analysis of 
p-Akt/Akt ratio in relation to 
insulin-stimulated control 
cells (means±SE, n=3-4). 
Dunnett’s t-test was used to 
compare the values of statin-
treated groups and insulin-
stimulated control group. ＊p
＜0.05 versus control＋insu-
lin. Con, control; Pit, pitavas-
tatin; Ros, rosuvastatin; Ins, 
insulin; SE, standard error. 
Fig.4. Plasma adiponectin and high molecular weight 
(HMW) adiponectin level in different treatment 
groups
(a) Total adiponectin, (b) HMW adiponectin. Error bars represent 
standard error of mean. P values were generated by ANOVA. 
HFD, high-fat diet; Pitava, pitavastatin; Rosuva, rosuvastatin.
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and increased systemic bioavailability (≥ 51%) and it 
may strongly influence the systemic glucose uptake in 
peripheral cells such as myocytes and adipocytes17). 
However, in the present study, we found that the use 
of pitavastatin did not significantly affect the process 
of insulin signaling in the muscle or adipose tissue. 
This may serve as one of the reasons underlying the 
neutral effects of pitavastatin on glucose metabolism. 
Insulin signaling in the peripheral adipose tissue 
is mediated by the binding of insulin to the cell sur-
face receptors, resulting in the phosphorylation of 
insulin receptor substrates at specific tyrosine residues 
and activation of phosphatidylinositol 3-kinase and its 
downstream target Akt. Akt and the downstream tar-
gets have key roles in insulin sensitivity and normal 
glucose tolerance23, 24). Phosphoinositide-3,4,5-tri-
sphosphate produced by phosphatidylinositol 
3-kinase25) binds to the domain of Akt, allowing for 
its translocation to the cell membrane, followed by 
phosphorylation and activation within the catalytic 
domain T-loop (threonine 308) and the carboxyl ter-
minal hydrophobic domain (serine 473) and the sub-
sequent activation of many downstream targets26, 27). 
In the next step, it redistributes GLUT4 from the 
intracellular storage to the plasma membrane. There-
fore, the reduction in Akt activation in the adipose tis-
sue may potentially increase insulin resistance and the 
risk of diabetes. In addition, the differences in the 
expression of GLUT4 in adipocytes were thought to 
be one of the reasons for the observed differences in 
the effects of statins on glucose metabolism28). How-
ever, in the present study, the attenuation of Akt phos-
phorylation in adipocytes was lower in the presence of 
pitavastatin than with rosuvastatin treatment. In addi-
tion, the difference in Akt attenuation between 
pitavastatin and rosuvastatin groups led to the varia-
tion in GLUT4 translocation to the plasma mem-
brane and 2-DG uptake in adipocytes. 
Previous studies have reported attenuated insulin 
signaling and decreased GLUT4 translocation in adi-
pocytes when using atorvastatin29) or lovastatin30). In 
this study, rosuvastatin also showed a similar effect, 
while pitavastatin did not show such patterns. Previ-
ous studies in humans have shown increased insulin 
resistance following treatment with several statins, 
including rosuvastatin31). However, consistent with 
present study, pitavastatin was shown to exert no effect 
on blood glucose control and whole body insulin sen-
sitivity32). The mechanisms by which some statins may 
exert diabetogenic effects currently remain unclear. 
Several recent meta-analyses have suggested that a dif-
ferential effect on incidence of diabetes33) or insulin 
sensitivity34) may exist for different statins in human. 
Statins comprise many subtypes based on structural 
tatin treatment group showed lower fasting glucose 
level without any significant difference in food intake 
and weight gain. Considering the result of OGTT and 
ITT, the main reason underlying the difference in glu-
cose metabolism between the two statin groups was 
thought to be the variation in insulin resistance. We 
could confirm that this effect may be mediated by the 
reduced attenuation in insulin signaling in adipocytes.
Insulin-induced glucose uptake in the peripheral 
adipose tissue is crucial for the reduction in blood glu-
cose concentrations, and the defect in this process is 
one of the major causes of diabetes mellitus. The affin-
ity of pitavastatin toward hepatic LDL receptors is 
lower than that of other statins22). As a consequence, 
pitavastatin exhibits reduced hepatic absorption rate 
Fig.6. Statins differentially alter the insulin-induced 2-DG 
uptake and GLUT4 translocation in cultured adipo-
cytes
(a) Comparison of 2-DG uptake. Data represent means±SE of 
three independent experiments and are expressed as fold changes 
in glucose uptake relative to that with control＋insulin group. 
Dunnett’s t-test was used to compare the values of statin-treated 
groups and insulin-stimulated control group. ＊p＜0.05, ＊＊p＜0.01
(b) GLUT4 staining, A, Con; B, Con＋Ins; C, Pit＋Ins; D, Ros＋
Ins. GFP is shown in green (Scale bar: 10 µm (micrometer)).
GLUT4, glucose transporter 4; 2-DG, 2-deoxyglucose; Con, con-
trol; Pit, pitavastatin; Ros, rosuvastatin; Ins, insulin; SE, standard 
error; GFP, green fluorescent protein. 
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in determining fasting insulin level, as well as the 
function of beta cell secretion. In this study, there was 
no significant difference in the effect of statin on liver. 
As a result, this may lead to similar fasting insulin lev-
els. However, the direct effect of statins on the pan-
creas and the function of insulin secretion was not 
fully investigated in this study, and further studies will 
be needed to complement these factors. 
The present study also had several other limita-
tions. The change in serum cholesterol level was not 
measured. Therefore, whether the experiment was per-
formed under the conditions that produce similar 
effects on cholesterol remains a concern. In addition, 
the effect of pitavastatin was compared only with 
rosuvastatin; we could not confirm whether similar 
results could be reproducible with other statins. 
Despite these limitations, the study has several merits. 
We investigated the effects of pitavastatin on glucose 
metabolism via intracellular insulin signaling, insulin 
resistance, and glucose clearance in HFD-induced 
obese mice and several cell lines. Furthermore, we 
demonstrated that pitavastatin is less involved in the 
increased peripheral insulin resistance through the 
decreased attenuation of insulin-stimulated intracellu-
lar signaling via Akt phosphorylation and GLUT4 
translocation. 
Conclusion
Pitavastatin treatment reduced fasting blood glu-
cose and insulin resistance than rosuvastatin treat-
ment. This observation was associated with the 
improvement in peripheral insulin resistance, espe-
cially in the adipose tissue, via intracellular Akt activa-
tion and GLUT4 translocation. Pitavastatin may serve 
as a useful drug for the treatment of dyslipidemia in 
patients with a high risk of insulin resistance or hyper-
glycemia. 
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differences, resulting in different pharmacokinetics 
and efficacy. This structural difference between statins 
could lead to a difference in efficiency in transporta-
tion into the cell35) and differential diabetogenic 
effect. 
Clinical data have shown that pitavastatin 
increases plasma adiponectin and HMW adiponectin 
levels36-39), which are potent insulin sensitizers40, 41). 
This phenomenon is often presented as one of the 
important reasons underlying the lower risk of diabe-
tes with pitavastatin than with other statins. However, 
in the present study, no statistically significant differ-
ence was observed in the serum levels of adiponectin 
and HMW adiponectin in different treatment groups. 
The present findings provide evidence that pitavas-
tatin exerts neutral effects on insulin signaling and 
resistance without changing the levels of adiponectin. 
In previous studies, the possibility that the use of 
pitavastatin may directly act on fat tissue via preven-
tion of adipocyte hypertrophy42) and anti-adipogenic 
action43) was reported. We could not proceed with a 
related experiment in the current study, and instead, 
we measured the size of adipocyte (visceral) using a 
similar design model from a study conducted in our 
laboratory. The results also showed that the cell size in 
adipose tissue of pitavastatin treatment group was sig-
nificantly decreased compared to the high fat control 
or rosuvastatin treatment group (all p＜0.001 by 
ANOVA, Supplementary Fig.2). Likewise, the result 
of this study was consistent with those of previously 
reported studies in that the difference in the effect of 
pitavastatin on glucose metabolism, as compared with 
other statins, is mainly associated with the variation in 
its effect on adipocytes. 
In vitro experiments revealed the lack of any sig-
nificant difference in insulin signaling in hepatocytes 
and muscle cells from pitavastatin and rosuvastatin 
treatment groups. Only adipocytes from pitavastatin 
treatment group were less affected during insulin sig-
naling and were less involved in insulin resistance 
compared to those from rosuvastatin treatment group. 
Recent studies on statins have reported increased insu-
lin resistance in adipose tissue. Henriksbo et al. reported 
that statin activates caspase-1/IL-1β inflammasome 
responses and impairs endocrine control of adipocyte 
lipogenesis44). However, further studies will be needed 
to determine why these effects are specific for adipo-
cyte.
In the current study, insulin responsive secretion 
evoked by increased insulin resistance was not 
observed in rosuvastatin group. Increased insulin resis-
tance with persistent high fat diets could decrease the 
function of insulin secretion in rosuvastatin group. 
Also, hepatic gluconeogenesis plays an important role 
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Supplementary Fig.1. Statins differentially alter the insulin-induced 
phosphorylation of Akt in cultured cells
Primary adipocytes from the visceral fat tissue were treated with 10 µM of 
statins for 24 h, followed by stimulation with insulin for 5 to 15 min. (a) 
Visceral adipocytes from mice fed with high-fat diet.
Representative western blots are shown above the plots of densitometric 
analysis of p-Akt/Akt ratio in relation to insulin-stimulated control cells 
(means±SE, n=2). Dunnett’s t-test was used to compare the values 
between statin-treated groups and insulin-stimulated control group. ＊p＜
0.05 versus control＋insulin. Con, control; Pit, pitavastatin; Ros, rosuvas-
tatin; Ins, insulin.
Supplementary Fig.2. Statins differentially alter the size of adipocytes
Mice were fed a high-fat diet (HFD, including 45% fat, n=4), HFD with rosuvastatin (0.01%, 
n=3), or HFD with pitavastatin (0.01%, n=3) for 15 weeks, starting from 5 weeks of age .
Graph data were compiled to show the effects of pitavastatin and rosuvastatin on the diameter 
of adipocytes in a total of 1,200 adipocytes (n=120 per animal). Markedly increased size of adi-
pocytes were observed in both high fat control group and rosuvastatin treated group with high 
fat diet, but the sizes were less increased in pitavastatin treated group with high fat diet mouse 
model (all p＜0.001 by ANOVA test).
HFD, high fat diet control; Pitava, pitavastatin treated with high fat diet; Rosuva, rosuvastatin 
treated with high fat diet.
